
Claims


1. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 49)

or a salt thereof.

2. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 49).

3. The modified oligonucleotide of claim 1, which is the sodium salt or the potassium salt.

4. A pharmaceutical composition comprising the modified oligonucleotide of claim 1 and a pharmaceutically acceptable diluent or carrier.

5. The pharmaceutical composition of claim 4, comprising a pharmaceutically acceptable diluent, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).

6. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS).

7. A pharmaceutical composition comprising the modified oligonucleotide of claim 3 and a pharmaceutically acceptable diluent or carrier.

8. The pharmaceutical composition of claim 7, comprising a pharmaceutically acceptable diluent, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).

9. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS).

10. A pharmaceutical composition comprising the modified oligonucleotide of claim 2 and a pharmaceutically acceptable diluent or carrier.

11. The pharmaceutical composition of claim 10, comprising a pharmaceutically acceptable diluent, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).

12. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS).

13. A compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is a gapmer consisting of a 5’ wing segment, a central gap segment, and a 3’ wing segment, wherein:

the 5’ wing segment consists of six 2’-O-methoxyethyl nucleosides,

the central gap segment consists of ten β-D-deoxyribonucleosides, and

the 3’ wing segment consists of four 2’-O-methoxyethyl nucleosides;

wherein the modified oligonucleotide has the nucleobase sequence 5’-GGTTAATCTTTATCAGGTCT-3’ (SEQ ID NO: 49), wherein each cytosine is a 5-methylcytosine; and wherein the internucleoside linkages of the modified oligonucleotide are, from 5’ to 3’, sooooosssssssssssoss, wherein each s is a phosphorothioate linkage and each o is a phosphodiester linkage.

14. The compound of claim 13, comprising the modified oligonucleotide covalently linked to a conjugate group.

15. A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable diluent or carrier.

16. The pharmaceutical composition of claim 15, comprising a pharmaceutically acceptable diluent, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).

17. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition consists essentially of the compound and phosphate-buffered saline (PBS).

18. A pharmaceutical composition comprising the compound of claim 14 and a pharmaceutically acceptable diluent or carrier.

19. The pharmaceutical composition of claim 18, comprising a pharmaceutically acceptable diluent, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).

20. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition consists essentially of the compound and phosphate-buffered saline (PBS).